Program For The Second International Drug-Drug Interaction Workshop At Marbach Castle, Germany Finalized
The organisation team reports the final program of the DDI 2011 - 2nd International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions.
Online, January 20, 2011 (Newswire.com) - The topics of the 2nd Marbach Castle meeting on regulatory and scientific aspects of drug-drug interactions (DDI), which will take place from May 1st to 3rd 2011, will be covered by renowned international scientists and experts from academia, pharmaceutical companies, contract research organizations, and consultancies. The program will provide a unique opportunity for scientific exchange and networking across company and organizational borders, and an opportunity to learn about the current state-of-the-art in the investigation of DDIs.
The organizers are pleased to announce additional distinguished speakers from the USA (Michael Bolger, Uwe Christians, Andrew Parkinson, Alex Sparreboom, Karthik Venkatakrishnan) and Germany (Thomas Gramatte´, Wilhelm Haverkamp, Bernd Liedert, Christian de Mey).
More than 60 experts from 11 countries and 5 participants at the industry exhibition joined the first drug-drug-interaction (DDI) workshop, which was held from May 30th to June 01st at Marbach Castle last year. The big success of the scientific meeting and very positive feedback from the participants stimulated the organizers enormously to build up an ambitious program for this year.
The scientific sessions will cover different aspects to large molecule interactions, regulatory sciences, the role of M&S in regulatory aspects of DDIs, PK and PD DDIs in special therapeutic indications, non-metabolic DDIs in drug absorption as well as disposition. Robert Hermann, member of the organisation team, highlights:"It was very important for us to continue with the discussions of last year regarding the upcoming guideline changes in Europe and the United States. Although none of the guidelines is finalized as yet, we are willing to allocate time for this important topic and to compare the available European draft guideline and published evidence on the current thinking of the US-FDA in this matter."
This international Workshop on drug-drug interactions is designed to meet the requirements and expectations of professionals from the pharmaceutical industry, contract research organisations, regulatory agencies and academia. Department heads, project managers, scientists and consultants in
R&D, in regulatory affairs, pharmacokinetics, clinical pharmacology, exploratory medicine, clinical development, biostatistics, business development, medical communications and so forth should attend. All delegates are invited to contribute actively to the scientific discussions.
More information and register: http://www.cr-appliance.com
About the DDI Workshop
The DDI Workshop is an initiative of cr.appliance in cooperation with Hartmut Derendorf, Amin Rostami-Hodjegan, and Oliver von Richter. The meeting will take place in Marbach Castle Conference Centre, located at the Lake Constance, Germany.
The organizers of the DDI Workshop are:
• Hartmut Derendorf, PhD FCP; College of Pharmacy, University of Florida, USA
• Robert Hermann, MD FCP; cr.appliance, Germany
• Amin Rostami-Hodjegan, PhD FCP; Faculty of Medical and Human Sciences, University of Manchester, UK
• Oliver von Richter, PhD FCP; Dept. Exploratory Medicine, Merck Serono, Germany
Contact & Information:
Karen Grave-Hermann
Mail: karen.grave-hermann@cr-appliance.com
Phone: +49 (0)7732 820 951
Fax: +49 (0)7732 820 953
About cr.appliance
cr.appliance is an independent team of experts that supports its clients in the healthcare industry with counseling, development concepts and services during the early stages of clinical drug development and throughout the licensing process.
cr.appliance uses its well-documented, recognised expertise to the benefit of its clients.
The team of experts has undertaken successful project work in the pharmaceutical industry as well as work in the service sector (CROs), hospitals and academia. The team has a wealth of well-founded, up-to-date expertise. This, combined with many years of professional experience in a number of specialist fields and areas of work, enables them to provide high-quality consultancy, create sustainable and viable development concepts and offer customer-specific services in various aspects of drug development.
More information about cr.appliance: http://www.cr-appliance.com